- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05290155
Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies
November 26, 2023 updated by: Xianmin Song, MD, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
The Safety and Clinical Efficacy of Human CD7 CAR-T Cell Therapy for Patients With Relapsed/Refractory CD7 Positive T Cell Hematological Maliganacies
The purpose of this study is to evaluate the safety and efficacy of CAR T cell treatment targeting CD7 in patients with relapsed or refractory CD7 positive T-cell hematological maliganacies
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This study is single-armed,open lable,dose escalation clinical trial.The main purpose is to evaluate the safety and efficacy of anti-CD7 CAR-T cells in relapsed/refractory patients with CD7 positive T cell malignancies,including T lymphoblastic lymphoma/leukemia ,T-cell non-Hodgkin lymphoma(peripheral T cell lymphoma,NOS,angioimmunoblastic T cell lymphoma and anaplastic large cell lymphoma).There will be three CAR T cell dose groups:0.5*10^6
cells per kilogram of body weight;1*10^6 cells per kilogram of body weight,2 *10^6 ells per kilogram of body weight.
Study Type
Interventional
Enrollment (Estimated)
4
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Xianmin G Song, MD
- Phone Number: 02163240090
- Email: shongxm@139.com
Study Locations
-
-
-
Shanghai, China
- Recruiting
- Xianmin General Song
-
Contact:
- Xianmin G Song
- Phone Number: +862163240090
- Email: shongxm@139.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
14 years to 70 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion criteria
- Fourteen to 70 Years Old, Male and female;
- Expected survival > 12 weeks; ECOG score 0-2;
- Confirmed diagnosis of acute T cell leukemia and screened for CD7 positive,including following conditions:a. Patients who do not get a CR with ≥2 prior induction therapy b. Those who achieves CR, but have a early relapse(<12months),or a late relapse (>=12months) failing to acheive a CR after re-induction chemotherapy c. For any Patiens failed ASCT/allo-SCT
- Relapsed and refractory patients with diagnosis of CD7 positive T cell lymphoma have had≥2 prior lines of therapy,who do not acheive at least a PR, or have a relapse including:a. Peripheral T cell lymphoma NOS, or b.Angioimmunoblastic T cell lymphoma,or c. Anaplastic large cell lymphoma c.Disease can be assessed(BM or CT scan)
- Confirmed T lymphoblatic lymphoma:a. Patients who do not get a PR with ≥2 induction chemotherapy or a CR with ≥ 4 induction chemotherapy b. Relapsed patients failing to acheive a CR after 1 line salvage chemotherapy c. For any Patiens failed ASCT/allo-SCT d.Disease can be assessed(BM or CT scan)
- The venous access required for collection can be established and mononuclear cell collection can be determined by the investigators;
- Liver, kidney and cardiopulmonary functions meet the following requirements: a. Ccr≥60mL/min(Cockcroft Gault) b. Left ventricular ejection fraction >50%; c.Baseline oxygen saturation>92%; d. Total bilirubin ≤ 1.5×ULN; e. ALT and AST≤ 3×ULN;
- Able to understand and sign the Informed Consent
Exclusion Criteria:
- Malignant tumors other than T cell malignancies within 5 years prior to screening, in addition to adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, localized prostate cancer after radical resection, and ductal carcinoma in situ after radical resection;
- Uncontrolled infection including bacteral or virus or fugal disease;patients with positive HBsAg or HBcAb and positive peripheral blood HBV DNA titer detection ;HCV antibody positive and peripheral blood HCV RNA positive; HIV antibody positive; syphilis positive;
- Any instability of systemic disease, including but not limited to unstable angina, cerebrovascular accident, or transient cerebral ischemic (within 6 months prior to screening),myocardial infarction (within 6 months prior to screening), congestive heart failure (New York heart association (NYHA) classification ≥ III), need drug therapy of severe arrhythmia,liver, kidney, or metabolic disease;
- Any uncontrolled disease may affect entry
- Current or history of CNS involvement by malignancy.Known history or presence of clinically relevant central nervous system (CNS) pathology.Patients with a known history or prior diagnosis other immunologic or inflammatory disease affecting the CNS (such as epilepsy)
- Patients who are receiving systemic steroid treatment and requiring long-term systemic steroid treatment during the treatment as determined by the investigator before screening (except inhalation or topical use); And subjects treated with systemic steroids (except inhalation or topical use) within 72h prior to cell transfusion;
- Subjects treated with anti-PD1 or anti-PDL1 therapies within 3months before enrollment
- Pregnant or lactating woman, and female subject who plans to have a pregnancy within 1 year after cell transfusion, or male subject whose partner plans to have a pr egnancy within 1 year after cell transfusion;
- Active or uncontrollable infection requiring systemic therapy Received CAR-T treatment or other gene therapies before enrollment;
- Kown be allergic to anti-TRBC1 CAR-T cells or drugs(Fludarabine or Cyclophophamide)
- The investigators consider other conditions unsuitable for enrollment.
- Patients who may not be able to sign the Informed Consent due to disease,or who do not understand or unwillingness or inability to comply with research requirements
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Anti-CD7 CAR T cells
Administration with anti-CD7 CAR-T cells in the relapsed/refractory T cell hematological malignancy patients
|
Administration with anti-CD7 CAR-T cells in the relapsed/refractory T cell hematological malignancy patients
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Treatment-Emergent Adverse Events
Time Frame: 28 days post infusion
|
The occurence of study related adverse effects defined by NCI CTCAE5.0
|
28 days post infusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of remission (DOR) after administration
Time Frame: 2 years post infusion
|
Duration of remission (DOR) after administration
|
2 years post infusion
|
CAR-T cell expansion
Time Frame: 2 years post infusion
|
Using flow cytometry to reveal cell surface expression of the CAR protein on T cells;and using quantitative polymerase chain reaction to detect DNA copies of the transgene irrespective of gene expression(per ug DNA) to evaluate anti-CD7 CAR-T cell expansion after infusion
|
2 years post infusion
|
CAR-T cell persistence
Time Frame: 2 years post infusion
|
Using flow cytometry to reveal cell surface expression of the CAR protein on T cells;and using quantitative polymerase chain reaction to detect DNA copies of the transgene irrespective of gene expression(per ug DNA) to evaluate anti-CD7 CAR-T cell persistence after infusion
|
2 years post infusion
|
Number of CD7+ lymphocytes of peripheral blood
Time Frame: 2 years post infusion
|
To evaluate CD7 positive cells of peripheral blood after infusion
|
2 years post infusion
|
Total response rate (ORR) after administration
Time Frame: 3 months post infusion
|
CR+CRi for T-ALL ;CR+PR for T cell lyphoma and T lymphoblastic lymphoma
|
3 months post infusion
|
Overall survival(OS) after administration
Time Frame: 2 years post infusion
|
Overall Survival (OS)after administration
|
2 years post infusion
|
Progression Free Survival (PFS) after administration
Time Frame: 2 years post infusion
|
Progression Free Survival (PFS) after administration
|
2 years post infusion
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immunogenicity of CAR-T cells
Time Frame: 2 years post infusion
|
Using flow cytometry to detect whether anti-car antibodies are contained in serum of patients receiving CAR-T cells infusion,and to evaluate the number of participants with antibodies
|
2 years post infusion
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Xianmin G Song, M.D., Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 4, 2022
Primary Completion (Estimated)
August 1, 2024
Study Completion (Estimated)
November 1, 2024
Study Registration Dates
First Submitted
March 9, 2022
First Submitted That Met QC Criteria
March 18, 2022
First Posted (Actual)
March 22, 2022
Study Record Updates
Last Update Posted (Actual)
November 28, 2023
Last Update Submitted That Met QC Criteria
November 26, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Lymphadenopathy
- Lymphoma
- Leukemia
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Leukemia, Lymphoid
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Peripheral
- Lymphoma, Large-Cell, Anaplastic
- Immunoblastic Lymphadenopathy
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Other Study ID Numbers
- SHYSXY-202105-CD7-CART
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anaplastic Large Cell Lymphoma
-
Jun ZhuPeking University First Hospital; Peking University People's Hospital; Peking... and other collaboratorsWithdrawnSystemic Anaplastic Large-Cell LymphomaChina
-
Bristol-Myers SquibbWithdrawnLymphoma, Large-CellUnited States, France
-
National Cancer Institute (NCI)Active, not recruitingAnaplastic Large Cell Lymphoma, ALK-Positive | Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma | Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma | Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell LymphomaUnited States
-
Seagen Inc.CompletedLarge Cell LymphomaUnited States
-
Children's Cancer Group, ChinaQilu Hospital of Shandong University; Shanghai Children's Medical Center; West... and other collaboratorsRecruitingPediatric Anaplastic Large Cell LymphomaChina
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...Not yet recruitingHodgkin Lymphoma | Non-Hodgkin Lymphoma | Peripheral T-cell Lymphoma | Anaplastic Large Cell Lymphoma, ALK-Positive | Anaplastic Large Cell Lymphoma, ALK-negative | CD30-Positive Diffuse Large B-Cell Lymphoma | Anaplastic Large Cell Lymphoma, T Cell and Null Cell TypeUnited States
-
University of WashingtonNational Cancer Institute (NCI)WithdrawnAnaplastic Large Cell Lymphoma, ALK-Positive | CD30-Positive Neoplastic Cells Present | Systemic Anaplastic Large Cell LymphomaUnited States
-
University Hospital, ToulouseInstitut National de la Santé Et de la Recherche Médicale, FranceActive, not recruitingALK-Positive Anaplastic Large Cell LymphomaFrance
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownRelapsed/Refractory Anaplastic Large Cell Lymphoma (ALCL)China
-
Fox Chase Cancer CenterWithdrawnAnaplastic Large Cell Lymphoma, ALK-PositiveUnited States
Clinical Trials on anti-CD7 CAR-T cells
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingAutoimmune Diseases | Crohn Disease | Ulcerative Colitis | Dermatomyositis | Still DiseaseChina
-
Shenzhen University General HospitalRecruiting
-
iCell Gene TherapeuticsPeking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.RecruitingT-cell Acute Lymphoblastic Leukemia | T-cell Non-Hodgkin Lymphoma | T-cell Acute Lymphoblastic LymphomaChina
-
Bioceltech Therapeutics, Ltd.RecruitingT Cell Lymphoblastic LymphomaChina
-
The First Affiliated Hospital of Soochow UniversityAffiliated Hospital of Jiangnan University; The Affiliated Nanjing Drum Tower... and other collaboratorsRecruiting
-
Shenzhen Geno-Immune Medical InstituteThe Second Affiliated Hospital of Hainan Medical University; Beijing Jingdu...RecruitingAcute Myeloid Leukemia | T-cell Acute Lymphoblastic Leukemia | T-cell Acute Lymphoblastic Lymphoma | NK Cell LymphomaChina
-
Shenzhen Geno-Immune Medical InstituteRecruitingAcute Myeloid Leukemia | T-cell Acute Lymphoblastic Leukemia | T-cell Acute Lymphoblastic Lymphoma | NK Cell LymphomaChina
-
Ying WangRecruiting
-
Beijing GoBroad HospitalRecruitingAcute Lymphoblastic Leukemia, in Relapse | Refractory Acute Lymphoblastic Leukemia | T-cell Acute Lymphoblastic LeukemiaChina
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingNeoplasms | Hematologic DiseasesChina